Literature DB >> 26600762

Radiotherapy of Ductal Carcinoma In Situ.

David Krug1, Rainer Souchon2.   

Abstract

Ductal carcinoma in situ (DCIS) is a heterogeneous disease in both its biology and clinical course. In the past, recurrence rates after breast-conserving surgery have been as high as 30% after 10 years. The introduction of mammography screening and advances in imaging have led to an increase in the detection of DCIS. The focus of this review is on the role of radiotherapy in the multidisciplinary treatment, including current developments in hypofractionation and boost delivery, and attempts to define low-risk subsets of DCIS for which the need for adjuvant radiation is repeatedly questioned.

Entities:  

Keywords:  Boost; Ductal carcinoma in situ (DCIS); Hypofractionation; Low-risk subgroup; Radiotherapy

Year:  2015        PMID： 26600762      PMCID： PMC4608608          DOI： 10.1159/000437452

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


  37 in total

1.  Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial.

Authors:  Fredrik Wärnberg; Hans Garmo; Stefan Emdin; Veronica Hedberg; Linda Adwall; Kerstin Sandelin; Anita Ringberg; Per Karlsson; Lars-Gunnar Arnesson; Harald Anderson; Karin Jirström; Lars Holmberg
Journal:  J Clin Oncol       Date:  2014-10-13       Impact factor: 44.544

2.  Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network.

Authors:  Aurelius Omlin; Maurizio Amichetti; David Azria; Bernard F Cole; Philippe Fourneret; Philip Poortmans; Diana Naehrig; Robert C Miller; Marco Krengli; Cristina Gutierrez Miguelez; David Morgan; Hadassah Goldberg; Luciano Scandolaro; Pauline Gastelblum; Mahmut Ozsahin; Dagmar Dohr; David Christie; Ulrich Oppitz; Ufuk Abacioglu; Guenther Gruber
Journal:  Lancet Oncol       Date:  2006-08       Impact factor: 41.316

3.  Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS).

Authors:  Sevilay Altintas; Jerome Toussaint; Virginie Durbecq; Kathleen Lambein; Manon T Huizing; Denis Larsimont; Eric Van Marck; Jan B Vermorken; Wiebrem A Tjalma; Christos Sotiriou
Journal:  Breast J       Date:  2011-06-06       Impact factor: 2.431

4.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Authors:  Karla Kerlikowske; Annette M Molinaro; Mona L Gauthier; Hal K Berman; Fred Waldman; James Bennington; Henry Sanchez; Cynthia Jimenez; Kim Stewart; Karen Chew; Britt-Marie Ljung; Thea D Tlsty
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

5.  RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.

Authors:  Beryl McCormick; Kathryn Winter; Clifford Hudis; Henry Mark Kuerer; Eileen Rakovitch; Barbara L Smith; Nour Sneige; Jennifer Moughan; Amit Shah; Isabelle Germain; Alan C Hartford; Afshin Rashtian; Eleanor M Walker; Albert Yuen; Eric A Strom; Jeannette L Wilcox; Laura A Vallow; William Small; Anthony T Pu; Kevin Kerlin; Julia White
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

6.  Role of radiotherapy boost in women with ductal carcinoma in situ: a single-center experience in a series of 389 patients.

Authors:  I Meattini; L Livi; D Franceschini; C Saieva; F Meacci; L Marrazzo; B Bendinelli; V Scotti; C De Luca Cardillo; J Nori; L Sanchez; L Orzalesi; P Bonomo; D Greto; M Bucciolini; S Bianchi; G Biti
Journal:  Eur J Surg Oncol       Date:  2013-03-20       Impact factor: 4.424

7.  Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group.

Authors:  Lorie L Hughes; Molin Wang; David L Page; Robert Gray; Lawrence J Solin; Nancy E Davidson; Mary Ann Lowen; James N Ingle; Abram Recht; William C Wood
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

8.  Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy.

Authors:  Raquel Ciervide; Shubhada Dhage; Amber Guth; Richard L Shapiro; Deborah M Axelrod; Daniel F Roses; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-01       Impact factor: 7.038

Review 9.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

Authors:  C Correa; P McGale; C Taylor; Y Wang; M Clarke; C Davies; R Peto; N Bijker; L Solin; S Darby
Journal:  J Natl Cancer Inst Monogr       Date:  2010

10.  The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Authors:  Joanne S Haviland; J Roger Owen; John A Dewar; Rajiv K Agrawal; Jane Barrett; Peter J Barrett-Lee; H Jane Dobbs; Penelope Hopwood; Pat A Lawton; Brian J Magee; Judith Mills; Sandra Simmons; Mark A Sydenham; Karen Venables; Judith M Bliss; John R Yarnold
Journal:  Lancet Oncol       Date:  2013-09-19       Impact factor: 41.316
View more
  4 in total

1.  [Optimal margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ : Results of the ASTRO, ASCO, and SSO consensus guideline].

Authors:  Rainer Souchon
Journal:  Strahlenther Onkol       Date:  2017-10       Impact factor: 3.621

2.  [Omission of adjuvant radiotherapy in ductal carcinoma in situ : 12 year-results of the ECOG-ACRIN E5194-trial].

Authors:  David Krug; Rainer Souchon
Journal:  Strahlenther Onkol       Date:  2016-05       Impact factor: 3.621

3.  Hypofractionation with concomitant boost using intensity-modulated radiation therapy in early-stage breast cancer in Mexico.

Authors:  María Yicel Bautista Hernandez; Pomponio José Lujan Castilla; Abril Antonia Quézada Bautista
Journal:  Rep Pract Oncol Radiother       Date:  2018-07-26

Review 4.  Current controversies in radiotherapy for breast cancer.

Authors:  David Krug; René Baumann; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Marc D Piroth; Marie-Luise Sautter-Bihl; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Rolf Sauer
Journal:  Radiat Oncol       Date:  2017-01-23       Impact factor: 3.481
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.